Guardant Health, Inc. GH
NASDAQ · United States · Health Technology
$178.36+0.63 (+0.35%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Abbott will sell Freenome’s SimpleScreen CRC test in the U.S. alongside the Cologuard Plus stool-based test it gained in the $21 billion acquisition of Exact Sciences.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.
Brian Shaw and Constantine Malaxos join as enterprise customers expand across financial services, healthcare, and technologySAN FRANCISCO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Coverbase, AI engineered for third-party risk management (TPRM), today announced that Brian Shaw has joined as GTM Lead and Constantine Malaxos as Head of Alliances. Both bring decades of experience building and selling third-party risk technology to large enterprises. In less than a year since closing its Series A, Coverbas
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.